personalized cancer
Genentech to End $2B Cell Therapy Collaboration with Adaptive Biotechnologies
Genentech; Adaptive Biotechnologies; cell therapy; collaboration termination; T-cell receptor; TruTCR platform; personalized cancer therapy; $2 billion deal
Personalized Cancer Vaccine Shows Promise in Preventing Recurrence of Advanced Kidney Cancer
personalized cancer vaccine, kidney cancer, clear cell renal cell carcinoma (ccRCC), neoantigen, immunotherapy, cancer recurrence prevention, phase 1 trial